stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
120.45
1.32
+1.11%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) EBITDA
GRAIL, Inc.'s EBITDA for fiscal 2025 was −$399.0M, compared with −$613.3M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$400.6M. GRAIL, Inc. ranks 48th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$399.0M | — |
| FY2024 | −$613.3M | — |
| FY2023 | −$638.2M | — |
| FY2022 | −$587.7M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$115.9M | — |
| Mar 2026 | −$103.5M | — |
| Dec 2025 | −$90.1M | — |
| Sep 2025 | −$91.1M | — |
| 8 more quarters | Free account |
EBITDA against peers
| Company | EBITDA |
|---|---|
| ICLR ICON PLC compare | $1.1B |
| QGEN QIAGEN N.V. compare | $651.0M |
| SHC Sotera Health Company compare | $537.0M |
| RDNT RadNet, Inc. compare | $307.7M |
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| BLLN BillionToOne, Inc. compare | $55.6M |
| ADPT Adaptive Biotechnologies Corporation compare | −$22.4M |
| GRAL GRAIL, Inc. | −$400.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement